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Abstract 
This retrospective series explores temozolomide monotherapy in elderly patients with primary 
CNS lymphoma (PCNSL) and severe comorbidities. In 17 patients (62-90 years old), 
complete response rate was 47%, median progression-free survival was five months and 
median overall survival was 21 months.  Five of 17 patients (29.4%) had prolonged responses 
for at least 12 months and survived for more than 24 months. Three of these patients had a 
methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter while the MGMT 
status was not assessable in the remaining two patients. Temozolomide monotherapy appears 
to be effective in a subgroup of elderly PCNSL patients and deserves further evaluation. 
 
Keywords: Primary central nervous system lymphoma - Chemotherapy - Temozolomide - 
MGMT
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Introduction 
High-dose methotrexate (HD-MTX)- based chemotherapy is the standard therapy for patients 
with primary CNS lymphoma (PCNSL). This treatment can also be applied to elderly patients 
without substantial toxicity as long as organ functions, especially renal function, are adequate 
[1]. Some elderly patients, however, cannot receive HD-MTX due to more markedly impaired 
renal function (creatinin clearance < 50 ml/min) or other comorbidity. No standard of care has 
been defined for this group of patients. Whole brain radiotherapy (WBRT) may not be 
appropriate because of the increased risk of late neurotoxicity in the elderly and its overall 
limited efficacy with a median survival time of 12 months [2]. This warrants the search for 
new chemotherapy regimens for these patients. The alkylating agent temozolomide (TMZ) 
penetrates well into the brain and has shown some efficacy in the second-line therapy of 
PCNSL [3-5]; furthermore, it is likely to be tolerated better than HD-MTX in patients with 
comorbidities. Thus, TMZ may be a promising treatment for elderly patients with PCNSL 
who cannot receive HD-MTX. As O6-methylguanine-DNA methyltransferase (MGMT) gene 
promoter methylation is highly predictive for survival in TMZ-treated glioblastoma patients 
[6], we also determined the MGMT promoter methylation status in the majority of our 
patients.  
  
Patients and methods 
We reviewed the charts of four German medical centers to identify PCNSL patients treated 
with primary TMZ chemotherapy, and analyzed toxicity, response to therapy and survival 
parameters in these patients. The best response to therapy was assessed in the absence of 
steroids by contrast-enhanced MRI according to the criteria established by Macdonald et al. 
[7]. Toxicity was graded according to the World Health Organization classification. 
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For the analysis of the MGMT promoter methylation status, genomic DNA was extracted 
from formalin-fixed paraffin-embedded tumor samples and subjected to bisulfite conversion 
using the EZ DNA Methylation-Gold KitTM (HISS Diagnostics, Freiburg, Germany) or the 
EpiTect Bisulfite Kit (Qiagen, Hilden, Germany). Bisulfite converted DNA was then analyzed 
by the authors using methylation-specific PCR (MSP) [8] or direct pyrosequencing [9] in all 
patients with a sufficient amount of paraffin-embedded tumor tissue available (for detailed 
descriptions of the methylation assays see refs. 8 and 9).  
 
Results 
Seventeen patients with histologically proven PCNSL and a median age of 75 years (range 
62-90 years; Table 1) who received first-line therapy with TMZ (100-200 mg/m2 on days 1 to 
5 of a 28-day-cycle) were identified. Two of the 17 patients have been previously reported 
[10]. HD-MTX therapy was regarded inappropriate because of impaired renal function 
(patients 3, 4, 6, 12 of Table 1), high age (patients 5, 7, 9, 11, 13-17), problems with fluid and 
electrolyte balance due to a syndrome of inadequate antidiuretic hormone secretion (SIADH; 
patient 1), extensive edema (patient 2), severe cardiovascular disease (patient 10), or non-
compliance due to oligophrenia (patient 8). The median number of TMZ cycles applied was 
three (range 1-8 cycles).  
 
Two patients (12%) developed WHO high-grade hematoxicity: patient 3 had grade 4 
leukopenia and thrombocytopenia with subsequent severe infection; patient 4 had grade 4 
leukopenia and grade 3 thrombopenia. One patient (#8) developed grade 1 skin erythema 
which might possibly be associated with TMZ therapy. One patient (#15) had to discontinue 
treatment due to spondylodiscitis and another patient (#5) had grade 2 colitis with unclear 
causal association to TMZ therapy. 
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Eight patients (47%) had a complete response (CR), one patient had a partial response (PR) 
and another eight patients had progressive disease (PD) (Table 1). The median progression-
free survival (mPFS) was five months (range 1-72+ months; Fig. 1a). Five of 17 patients 
(29.4%) had prolonged responses for more than 12 months. The median overall survival 
(mOS) was 21 months (range 1-72+ months; Fig. 1b). The estimated two-year survival rate 
was 39.7%. Second- and third-line therapies are listed in Table 1. In four patients (patients 2, 
4, 5, and 12), progression-free survival (PFS) after second-line WBRT was longer than PFS 
after primary TMZ chemotherapy.  
 
Tumor specimens of ten patients were available for MGMT analysis. MGMT promoter 
methylation (mMGMT; Table 1) in the tumor tissue was found in six patients, while four 
patients had a non-methylated MGMT promoter (nmMGMT). Overall survival was 21+ 
months in the group of mMGMT patients whereas mOS was 9 months in the group of 
nmMGMT patients. Furthermore, mPFS was 5+ months in mMGMT patients and 3 months in 
nmMGMT patients. Of note, three of the five patients surviving for 24 months or more had a 
methylated MGMT promoter while MGMT was not assessable in two of these patients.  
 
Discussion 
First-line chemotherapy with TMZ shows good tolerability and some activity in elderly 
PCNSL patients. CR rate (47%), mPFS (5 months) and mOS (21 months) compare well to 
presumably more toxic regimens such as chemotherapy on a HD-MTX, lomustine and 
procarbazine base (CR rate 42-47%, mPFS 5.9-6.8 months and mOS 14.3-15.4 months) [11, 
12]. Survival with TMZ monotherapy is somewhat shorter than with a combination of HD-
MTX and TMZ (CR 55%, mPFS 8 months, mOS 35 months) [13]. However, it is possible 
that selection bias negatively impacted survival data in our study because many older patients 
with severe comorbidities participated in the study. 
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Similar to what has been shown for the combination of HD-MTX/lomustine/procarbazine 
[12], our patient population falls into two subgroups: (1) the larger group of patients not at all 
responding to chemotherapy or rapidly progressing after a very short period of response and 
(2) the smaller group of patients deriving notable benefit from chemotherapy with extended 
PFS and a high potential for long-term survival (four of 17 patients surviving relapse-free for 
substantially more than two years). Our MGMT promoter methylation data is compatible with 
the notion that sustained response and prolonged survival are not possible in the presence of a 
non-methylated MGMT promoter (PFS 1-3 months). Since none of the patients surviving 
more than 24 months had a non-methylated MGMT promoter, it may be speculated that a 
methylated MGMT promoter is a necessary prerequisite for a sustained response. However, a 
methylated MGMT promoter cannot be the only molecular factor influencing response and 
survival since 3 of our patients with a methylated MGMT promoter nevertheless had a short 
PFS of less than 5 months. Certainly, our limited MGMT data does not sufficiently 
substantiate this hypothesis which has to be further explored in trials that apply alkylating 
agents to patients with PCNSL. Only larger trials will then allow to statistically compare 
survival parameters between mMGMT and nmMGMT patients. Of note, salvage WBRT was 
an effective therapy in four of five patients.  
 
The treatment of elderly patients with PCNSL remains a challenge. According to our 
preliminary data, TMZ therapy may be an option for some of these patients. The efficacy of 
TMZ therapy and a potentially predictive power of the MGMT promotor status have to be 
further explored in larger prospective trials which should also include quality of life 
assessments.  
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Fig. 1 Kaplan-Meier estimates are shown for (a) progression-free survival (median, 5 months) 
and (b) overall survival (median, 21 months) in 17 elderly patients with primary central 
nervous system lymphoma treated with first-line TMZ chemotherapy 
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Table 1  Patient characteristics, treatment outcome and MGMT promoter methylation  
status of patients with primary central nervous system lymphoma treated with first-line 
temozolomide (TMZ) 
Pat. 
No. 
Age at diagnosis 
[years], Gender 
Dose [mg/m2/d], 
No. of TMZ cyclesa
Response 
to TMZb
PFS 
[months] 
Further therapy at 
relapse (response) 
OS 
[months] 
MGMT 
status 
1 63, m 200, 8 cycles CR 72+ Still in CR 72+ + 
2 75, f 200, 4 cycles CR 5 7 x TMZ (PR) and 
WBRT (CR) 
21 NA 
3 78, f 200, 1 cycle CR 21 1 x PCV (NA), 
WBRT (CR) 
33 NA 
4 72, f 150, 3 cycles PR 5 WBRT (CR) 21 + 
5 72, f 200, 3 cycles PD 3 WBRT (NA) 8 - 
6 77, f 200, 1 cycle PD 1 None 1 NA 
7 90, f 100, 3 cycles CR 5 None 7 NA 
8 62, m 200, 1 cycle  CR 5 3 x TMZ (PD), 
PCV (NA) 
9 - 
9 88, f 100, 4 cycles PD 4 Rituximab (NA) 5+ NA 
10 73, m 200, 2 cycles CR 24+ Still in CR 24+ + 
11 82, f 150, 1 cycle PD 1 None 2 + 
12 67, f 200, 2 cycles PD 3 WBRT (CR) 16+ - 
13 81, m 150, 1 cycle PD 1 None 1 - 
14 75, f 150, 1 cycle  PD 1 None 2 + 
15 74, m 150, 1 cycle CR 26+ Still in CR 26+ NA 
16 85, m 150, 3 cycles PD 2 None 3 NA 
17 80, f 200, 8 cycles CR 29+ Still in CR 29+ + 
 
a All patients received standard TMZ treatment (days 1 to 5 out of a 28-day-cycle); b all patients were off steroids at the  
time of response evaluation 
Abbreviations: Pat. No. patient number; m male; f female; NA not assessable; PFS progression-free survival; OS overall 
survival; CR complete response; PR partial response; PD progressive disease; TMZ temozolomide; PCV procarbazine,  
CCNU, vincristine; WBRT whole brain radiotherapy (39.6-45 Gy); MGMT O6-methylguanine-DNA methyltransferase;  
+ methylated MGMT promoter; - non-methylated MGMT promoter 
 
  
